Revealing Breakthrough Mitochondrial Science for IPF

Time: 4:00 pm
day: Day Two


  • Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF
  • Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition.
  • Discuss other potential antifibrotic indications for CB5138-3